{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:40:03Z","timestamp":1762958403665,"version":"3.45.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,12]]},"DOI":"10.7759\/cureus.96665","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:33:43Z","timestamp":1762958023000},"source":"Crossref","is-referenced-by-count":0,"title":["Persistent BCR::ABL1 p190 Minimal Residual Disease and Declining Donor Chimerism Following Haploidentical Bone Marrow Transplant in Pediatric Acute Myeloid Leukemia With Dual High-Risk Fusions"],"prefix":"10.7759","author":[{"given":"Mohammed A","family":"Bafail","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AbdullabAli","family":"PeerZada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeh","family":"Alrajeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal M","family":"Alseraya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haya S","family":"AlJurayb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2020.100233","article-title":"Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1","volume":"15","author":"Takeuchi A","year":"2021","unstructured":"Takeuchi A, Kondo T, Tasaka T, et al.. Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1. Leuk Res Rep. 2021, 15:100233. 10.1016\/j.lrr.2020.100233","journal-title":"Leuk Res Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020458","article-title":"3q26.2\/MECOM rearrangements by Pericentric Inv(3): diagnostic challenges and clinicopathologic features","volume":"15","author":"Tang Z","year":"2023","unstructured":"Tang Z, Wang W, Yang S, et al.. 3q26.2\/MECOM rearrangements by Pericentric Inv(3): diagnostic challenges and clinicopathologic features. Cancers (Basel). 2023, 15:458. 10.3390\/cancers15020458","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2012.0105","article-title":"Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?","volume":"10","author":"Ravandi F","year":"2012","unstructured":"Ravandi F, Jorgensen JL. Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?. J Natl Compr Canc Netw. 2012, 10:1029-36. 10.6004\/jnccn.2012.0105","journal-title":"J Natl Compr Canc Netw"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.02.003","article-title":"Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia","volume":"24","author":"Shah MV","year":"2018","unstructured":"Shah MV, Jorgensen JL, Saliba RM, et al.. Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia. Biol Blood Marrow Transplant. 2018, 24:1514-20. 10.1016\/j.bbmt.2018.02.003","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8917","article-title":"A rare presentation of BCR-ABL1 and RUNX1-MECOM rearrangement in a pediatric patient with acute myeloid leukemia","volume":"12","author":"Alamri RM","year":"2024","unstructured":"Alamri RM, Alanazi M, AlRajeh RK, Tashkandi SA, Alswayyed AF, Samman MA, Peer-Zada AA. A rare presentation of BCR-ABL1 and RUNX1-MECOM rearrangement in a pediatric patient with acute myeloid leukemia. Clin Case Rep. 2024, 12:e8917. 10.1002\/ccr3.8917","journal-title":"Clin Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015441","article-title":"Deciphering potential molecular signatures to differentiate acute myeloid leukemia (AML) with BCR::ABL1 from chronic myeloid leukemia (CML) in blast crisis","volume":"24","author":"Boucher L","year":"2023","unstructured":"Boucher L, Sorel N, Desterke C, et al.. Deciphering potential molecular signatures to differentiate acute myeloid leukemia (AML) with BCR::ABL1 from chronic myeloid leukemia (CML) in blast crisis. Int J Mol Sci. 2023, 24:15441. 10.3390\/ijms242015441","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24928","article-title":"Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: a survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT)","volume":"93","author":"Lazarevic VL","year":"2018","unstructured":"Lazarevic VL, Labopin M, Depei W, et al.. Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: a survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT). Am J Hematol. 2018, 93:31-9. 10.1002\/ajh.24928","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1328858","article-title":"The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy","volume":"15","author":"Maurer K","year":"2024","unstructured":"Maurer K, Antin JH. The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy. Front Immunol. 2024, 15:1328858. 10.3389\/fimmu.2024.1328858","journal-title":"Front Immunol"},{"key":"ref9","article-title":"Efficacy of bone marrow transplantation in treating acute myeloid leukemia: a systematic review and meta-analysis","volume":"15","author":"Li Y","year":"2023","unstructured":"Li Y, Zhou F. Efficacy of bone marrow transplantation in treating acute myeloid leukemia: a systematic review and meta-analysis. Am J Transl Res. 2023, 15:1-12.","journal-title":"Am J Transl Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720948743","article-title":"Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation","volume":"11","author":"Chen J","year":"2020","unstructured":"Chen J, Wang H, Zhou J, Feng S. Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation. Ther Adv Hematol. 2020, 11:2040620720948743. 10.1177\/2040620720948743","journal-title":"Ther Adv Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150250","article-title":"Late effects of blood and marrow transplantation","volume":"102","author":"Inamoto Y","year":"2017","unstructured":"Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica. 2017, 102:614-25. 10.3324\/haematol.2016.150250","journal-title":"Haematologica"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.11.006","article-title":"Early mixed donor chimerism is a strong negative prognostic indicator in allogeneic stem cell transplant for AML and MDS","volume":"31","author":"Radford M","year":"2025","unstructured":"Radford M, Garcia-Horton A, Badami R, et al.. Early mixed donor chimerism is a strong negative prognostic indicator in allogeneic stem cell transplant for AML and MDS. Transplant Cell Ther. 2025, 31:77.e1-20. 10.1016\/j.jtct.2024.11.006","journal-title":"Transplant Cell Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2016.052","article-title":"Minimal residual disease in acute myeloid leukemia of adults: determination, prognostic impact and clinical applications","volume":"8","author":"Del Principe MI","year":"2016","unstructured":"Del Principe MI, Buccisano F, Maurillo L, et al.. Minimal residual disease in acute myeloid leukemia of adults: determination, prognostic impact and clinical applications. Mediterr J Hematol Infect Dis. 2016, 8:e2016052. 10.4084\/MJHID.2016.052","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13142","article-title":"Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia","volume":"168","author":"Sutton R","year":"2015","unstructured":"Sutton R, Shaw PJ, Venn NC, et al.. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol. 2015, 168:395-404. 10.1111\/bjh.13142","journal-title":"Br J Haematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002811","article-title":"Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML","volume":"4","author":"Short NJ","year":"2020","unstructured":"Short NJ, Rafei H, Daver N, et al.. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv. 2020, 4:6117-26. 10.1182\/bloodadvances.2020002811","journal-title":"Blood Adv"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis GJ","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, et al.. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018, 131:1275-91. 10.1182\/blood-2017-09-801498","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner H","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al.. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022, 140:1345-77. 10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, et al.. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020, 34:966-84. 10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-91936-7","article-title":"Impact of high-sensitivity flow cytometry on peri-transplant minimal residual disease kinetics in acute leukemia","volume":"15","author":"de Azambuja AP","year":"2025","unstructured":"de Azambuja AP, Beltrame MP, Malvezzi M, et al.. Impact of high-sensitivity flow cytometry on peri-transplant minimal residual disease kinetics in acute leukemia. Sci Rep. 2025, 15:6942. 10.1038\/s41598-025-91936-7","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06384-0","article-title":"Combination of pre-transplant flow cytometry, WT1 expression, and NGS for MRD monitoring is potent in predicting the prognosis of AML receiving allogeneic transplantation","volume":"104","author":"Liu J","year":"2025","unstructured":"Liu J, Guo D, Lian H, et al.. Combination of pre-transplant flow cytometry, WT1 expression, and NGS for MRD monitoring is potent in predicting the prognosis of AML receiving allogeneic transplantation. Ann Hematol. 2025, 104:2915-26. 10.1007\/s00277-025-06384-0","journal-title":"Ann Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/432039-persistent-bcrabl1-p190-minimal-residual-disease-and-declining-donor-chimerism-following-haploidentical-bone-marrow-transplant-in-pediatric-acute-myeloid-leukemia-with-dual-high-risk-fusions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:33:44Z","timestamp":1762958024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/432039-persistent-bcrabl1-p190-minimal-residual-disease-and-declining-donor-chimerism-following-haploidentical-bone-marrow-transplant-in-pediatric-acute-myeloid-leukemia-with-dual-high-risk-fusions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.96665","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}